VNDA vs. EBS, RIGL, CDXS, XOMA, IRWD, VSTM, SGMO, LXRX, ACHV, and AGEN
Should you be buying Vanda Pharmaceuticals stock or one of its competitors? The main competitors of Vanda Pharmaceuticals include Emergent BioSolutions (EBS), Rigel Pharmaceuticals (RIGL), Codexis (CDXS), XOMA (XOMA), Ironwood Pharmaceuticals (IRWD), Verastem (VSTM), Sangamo Therapeutics (SGMO), Lexicon Pharmaceuticals (LXRX), Achieve Life Sciences (ACHV), and Agenus (AGEN). These companies are all part of the "biotechnology" industry.
Vanda Pharmaceuticals vs.
Vanda Pharmaceuticals (NASDAQ:VNDA) and Emergent BioSolutions (NYSE:EBS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk, community ranking and media sentiment.
Vanda Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500.
Vanda Pharmaceuticals has higher earnings, but lower revenue than Emergent BioSolutions. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.
Vanda Pharmaceuticals received 116 more outperform votes than Emergent BioSolutions when rated by MarketBeat users. However, 66.77% of users gave Emergent BioSolutions an outperform vote while only 66.26% of users gave Vanda Pharmaceuticals an outperform vote.
In the previous week, Vanda Pharmaceuticals had 14 more articles in the media than Emergent BioSolutions. MarketBeat recorded 17 mentions for Vanda Pharmaceuticals and 3 mentions for Emergent BioSolutions. Vanda Pharmaceuticals' average media sentiment score of 0.53 beat Emergent BioSolutions' score of 0.20 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.
Vanda Pharmaceuticals presently has a consensus target price of $16.50, indicating a potential upside of 272.88%. Emergent BioSolutions has a consensus target price of $14.33, indicating a potential upside of 85.19%. Given Vanda Pharmaceuticals' higher probable upside, research analysts plainly believe Vanda Pharmaceuticals is more favorable than Emergent BioSolutions.
Vanda Pharmaceuticals has a net margin of -9.51% compared to Emergent BioSolutions' net margin of -18.55%. Vanda Pharmaceuticals' return on equity of -3.49% beat Emergent BioSolutions' return on equity.
88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.4% of Emergent BioSolutions shares are owned by institutional investors. 8.9% of Vanda Pharmaceuticals shares are owned by insiders. Comparatively, 1.2% of Emergent BioSolutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Vanda Pharmaceuticals beats Emergent BioSolutions on 12 of the 17 factors compared between the two stocks.
Get Vanda Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vanda Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:VNDA) was last updated on 2/21/2025 by MarketBeat.com Staff
Free VNDA Stock Alerts